The difference between information and
expert, data-driven actionable intelligence
Welcome to the January 2017 issue of CMC Market Outlook
This monthly e-newsletter provides valuable insights for both buyers and sellers of CMC drug development services. Our coverage will help you identify and understand market trends that will inform your strategic business perspective.
Enjoy the January issue!
The Tide Stays High
by Jim Miller, President
A year ago, the outlook for contract services was a little uncertain. Equity markets’ appetite for public offerings from emerging bio/pharmaceutical companies had significantly diminished: valuations of emerging bio/pharma companies, as measured by the NASDAQ Biotechnology Index (NBI), had declined by 15% from their highs in mid-2015, and by mid-February, they were off another 28%.
Because contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs) get so much of their business from externally-financed companies, the negative energy surrounding emerging bio/pharma did… read on
Catalent to Acquire Accucaps
Catalent has agreed to acquire softgel manufacturer Accucaps Industries Ltd. Financial details of the transaction were not disclosed, but analysts that follow Catalent put the price at $75 million, representing a multiple of 10x EBITDA. The deal is subject to Canadian regulatory approval.
Accucaps is owned by Canadian generic pharmaceutical company Apotex, a detail not mentioned in Catalent’s announcement. The company has two facilities, in Windsor and Strathroy, Ontario, and claims to have… read on
How big is the market for…?
This is a handy guide to frequently requested data about the bio/pharma contract services industry.
The market for total global bio/pharmaceutical R&D spending:
|2016: $127 billion
2020: $148 billion
Presentation at JP Morgan Conference
Read more about the size of the contract services market for various segments.
How much longer is the boom in the CDMO and CRO business likely to continue?
PharmSource Strategic Advantage
PharmSource’s STRATEGIC ADVANTAGE service is the industry’s most respected outsourcing information web portal for serious consumers of information on contract drug development and manufacturing. Developed from PharmSource’s expert proprietary research, you won’t find this information in any other resource.
See for yourself how this resource gives you vital tools for understanding the industry.
To request a test-drive today, contact email@example.com / +1-703-383-4903, ext. 112.